US Patent

US11744800 — Methods of use of emulsion formulations of an NK-1 receptor antagonist

Method of Use · Assigned to Heron Therapeutics LLC · Expires 2035-09-18 · 9y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects novel pharmaceutical formulations of an NK-1 receptor antagonist suitable for parenteral administration, including treatment of emesis in cancer chemotherapy patients.

USPTO Abstract

Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3690 — Emend

Patent Metadata

Patent number
US11744800
Jurisdiction
US
Classification
Method of Use
Expires
2035-09-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Heron Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.